INNO.CN - InnoCan Pharma Corporation

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2022-12-31
2021-12-31
2020-12-31
2019-12-31
Total Revenue
1,440
2,559
196
8
0
Cost of Revenue
919
452
75
5
-
Gross Profit
521
2,107
121
3
-
Operating Expenses
Research Development
1,480
1,526
1,399
1,365
368
Selling General and Administrative
6,171
6,847
6,202
3,236
2,633
Total Operating Expenses
7,651
8,373
7,601
4,728
3,001
Operating Income or Loss
-7,130
-6,266
-7,480
-4,725
-3,001
Interest Expense
2
2
13
5,228
334
Total Other Income/Expenses Net
3,806
2,359
-2,598
-
-
Income Before Tax
-3,324
-3,888
-10,091
-9,953
-3,335
Income Tax Expense
0
1
0
0
0
Income from Continuing Operations
-3,324
-3,889
-10,091
-9,953
-3,335
Net Income
-3,129
-3,764
-10,047
-9,953
-3,335
Net Income available to common shareholders
-3,129
-3,764
-10,047
-9,953
-3,335
Basic EPS
-
-0.02
-0.05
-0.06
-0.03
Diluted EPS
-
-0.02
-0.05
-0.06
-0.03
Basic Average Shares
-
248,953
224,542
162,022
120,644
Diluted Average Shares
-
248,953
224,542
162,022
120,644
EBITDA
-
-3,851
-10,035
-4,685
-2,978